Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment on Phosphocreatine Recovery in Obesity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men age 18-60 years old~2. BMI ≥ 30 kg/m2~3. Waist circumference ≥ 102 cm~4. Peak GH value of ≤ 4.2 μg/l on standard GHRH-arginine stimulation test~Exclusion Criteria:~1. Obesity due to a known secondary cause (Cushing's syndrome, hypothyroidism, etc) or a history of gastric bypass procedure.~2. Subjects who have a known history of diabetes, fasting blood sugar \>125 mg/dl or using any anti-diabetic drugs.~3. Use of Aspirin, Clopidogrel (Plavix), Warfarin (Coumadin) or other anti-coagulants~4. Subjects on testosterone, glucocorticoids, anabolic steroids, GHRH, GH or IGF-1 within 3 months of enrollment.~5. Changes in lipid lowering or anti-hypertensive regimen within 3 months of screening~6. History of pituitary tumor, hypopituitarism, pituitary surgery, pituitary/brain radiation or traumatic brain injury or any other condition known to affect the GH axis.~7. Severe chronic illness including HIV, active malignancy or history of colon cancer.~8. Hemoglobin \< 9.0 g/dL, SGOT \> 2.5 x upper limit normal, Creatinine \>1.5 mg/dL, or PSA \>5 ng/ml.~9. Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.~10. Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient.~11. Contraindications to MRI scanning.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Growth Hormone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).